Navigation Links
Intellikine Completes $51 Million Financing
Date:7/8/2009

LA JOLLA, Calif., July 8 /PRNewswire/ -- Intellikine, Inc., a leader in the development of innovative, small molecule drugs for the treatment of cancer, inflammation and autoimmune diseases, announced today that it has raised $51 million in preferred stock financing. Novartis Bioventures Ltd. led the financing in which additional new investors U.S. Venture Partners, Biogen Idec and FinTech Global Capital participated. Markus Goebel, M.D., Ph.D., Managing Director of the Novartis Venture Funds, will join the company's board of directors.

The investment includes a $28.5 million first closing. In addition, the company can access up to another $22.5 million, subject to the performance of certain milestones, which, if triggered, will bring the total amount raised in this round to $51 million. This latest financing comes less than two years after the company was formed with an initial investment of $12.5 million from founding investors Abingworth, CMEA Capital and Sofinnova Ventures, all of whom participated in this latest financing.

Intellikine is developing a portfolio of isoform-selective inhibitors of the phosphatidyinositol-3-kinase (PI3K) pathway for the treatment of cancer, inflammation and autoimmune diseases. The company has discovered multiple classes of proprietary compounds that are potent, selective and druglike inhibitors of PI3K isoforms. The company's most advanced compound, INK128, a selective TORC1/2 inhibitor, has demonstrated efficacy in multiple models of cancer and is expected to enter Phase I clinical studies within twelve months.

"We are delighted to have generated such excitement among both new and existing investors," said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Intellikine. "This financing gives us the resources necessary to advance our pipeline of PI3K/mTOR inhibitors into clinical development as well as significant flexibility to build strategic partner
'/>"/>

SOURCE Intellikine, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Funxional Successfully Completes Initial Clinical Trial of FX125L, an Anti-Inflammatory Drug With a Novel Mechanism of Action
2. Verenium Completes Amendment to 8% Senior Convertible Notes
3. Johnson & Johnson Completes Initial Tender Offer for Cougar Biotechnology
4. Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carboplatin Head and Neck Cancer Trial
5. Excalibur International Marine (49% Owned by EFT BioTech Holdings) Completes Inaugural Passenger Crossing of Taiwan Strait
6. EFT BioTech Holdings, Inc.s Sea Vessel Completes Inaugural Passenger Voyage Across the Taiwan Strait
7. Yaupon Therapeutics Completes Patient Enrollment for Pivotal Phase 2 Study of Clearazide for Treatment of Cutaneous T-cell Lymphoma
8. Cordex Completes Production of ATPace(TM) Clinical Trial Material
9. OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
10. Brooks Instrument Completes Acquisition of Celerity's Instrumentation Division
11. Sinovac Completes Construction of H1N1 Virus Seed Bank
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Clinverse, Inc. , a ... trials, announced today it has formed a strategic ... ClinPay® FLS eClinical commerce platform aggregates data collected ... SpendMD ™, Aggregate Spend Solutions’ recently-launched flagship product, ... reporting transfer of value at investigator meetings or ...
(Date:5/21/2013)... As the R&D sector becomes ... the industry to deliver better products, faster. Collaborations ... companies often means turning big ideas into reality, ... collaboration with Sensidose AB and Recipharm, is one ... to market sooner. The partnership resulted in the ...
(Date:5/21/2013)... ROCKVILLE, Md. , May 21, 2013 /PRNewswire/ ... "Phase 1 study of margetuximab (MGAH22), an Fc-modified ... solid tumors expressing the HER2 oncoprotein," will be ... American Society of Clinical Oncology during the Developmental ... June 3 at 4:15 – 4:30 PM.  The ...
(Date:5/21/2013)... Bed bugs have become so widespread in the past ... to chemical-based pesticides for help to completely get rid of ... solutions present, the company advised the public to kill ... According to My Cleaning Products, chemical-based pesticides are not as ... shared that the pests have already developed immunity to the ...
Breaking Biology Technology:Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 2New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 3
... to fund stem-cell research, under pressure from advocacy groups, have ... of the initiative's 29 board members hold significant stock in ... Bee reported. They won't have to relinquish stock or their ... Medicine will have to give up or put in a ...
... of raising capital for your business ", when raising ... should do is prepare a business plan. The business ... memorandum (PPM), the disclosure document that is typically circulated ... good draft of the business plan prepared, the people ...
... the first quarter of 2005 amid poor overall stock market ... the larger cap life science companies. Note that these results ... may have noticed headlines at the end of last week ... inhibitor (Bextra) off the market. , ,This stronger-than-expected action by ...
Cached Biology Technology:Due diligence and corporate clean-up 2Due diligence and corporate clean-up 3Due diligence and corporate clean-up 4Midwest large-cap life-science sector is solid in first quarter 2
(Date:5/21/2013)... of Michigan Water Center today awarded 12 research ... restoration and protection efforts. , The two-year grants ... including efforts to track the remediation of harmful ... control non-native weedy plant invasions; study chromosomal damage ... to restoration activities. , The grants were awarded ...
(Date:5/21/2013)... The American Chemical Society (ACS), the world,s largest ... 246th National Meeting & Exposition, September 8-12, 2013, ... the Indiana Convention Center and at area hotels. ... discoveries that span science,s horizons from astronomy ... broadcast and online journalists a rich assortment of ...
(Date:5/21/2013)... , May 21, 2013 Royal Philips Electronics ... the world,s first portable ultrasound with Philips, industry leading ... capability. The CX50 xMATRIX with available Live 3D TEE ... at the EuroPCR, official meeting for the ... Since its launch in 2012, Philips CX50 ...
Breaking Biology News(10 mins):U-M Water Center awards $570K in Great Lakes restoration grants 2U-M Water Center awards $570K in Great Lakes restoration grants 3U-M Water Center awards $570K in Great Lakes restoration grants 4Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2
... that may pave the way to helping reduce health ... make chemicals and drugs such as insulin cheaper to ... a three-dimensional model, Queen,s University biochemistry professor Zongchao Jia ... AceK protein acts as a switch in some bacteria ...
... most likely to occur on Sunday, in less than 6 ... wearing black and white bathing suits, a first of its ... analyzed statistics from shark attacks that occurred in Florida,s Volusia ... 1956 and 2008. They also spent a year observing people ...
... Studying whole microbial communities rather than individual micro-organisms could help ... climate change or pollution, says Dr Jack Gilbert writing in ... Marine microbes are responsible for 99% of the cycling of ... primary productivity. "Given the vital role of ocean microbes in ...
Cached Biology News:Discovery may lead to safer drinking water, cheaper medicine: Queen's University researchers 2Case study analyzes why, where and when of leading shark attack site 2Case study analyzes why, where and when of leading shark attack site 3Microbes answer more questions collectively 2
RAT ANTI MOUSE TCR V BETA 7:RPE Immunogen: T-cell lymphoma TK1...
... Serum • Rhesus serum is collected from ... years of age. Available Anticoagulants: ... (Na) N-06: K2EDTA N-08: ... N-03: Alsevers N-05: ACD ...
Porcine Serum US Origin 6 Months or Older...
SEQUENASE PCR PRODUCT PRE-SEQU, 1 EA. Category: SEQUENASE....
Biology Products: